Cargando…
RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127983/ https://www.ncbi.nlm.nih.gov/pubmed/37097476 http://dx.doi.org/10.1007/s00059-023-05168-4 |